Prof Trevor Jones CBE
Member of the Board & Chairman, eTherapeutics & Simbec Orion Research
PhD Hon DSc FRSC FRSM FKC Hon FRCP FFPM FBPharmacolS.
Professor Jones is a Director of Allergan Inc (USA) , Sigma Tau (Italy), Synexus Ltd and VeronaPharma plc.(UK) and President of Sigma-Tau Pharmaceuticals Inc (USA).
Between 1987-94 he was a main board director of The Wellcome Foundation, where he was responsible for R&D including the development of AZT (HIV/AIDS), Zovirax (Herpes), Lamictal (Epilepsy), Malarone (Malaria) and other medicines.
He is a visiting professor at King’s College, London and holds honorary degrees and Gold Medals from 6 universities.
He is a founder member of the Geneva-based, Public: Private Partnership, Medicines for Malaria Venture (MMV) and in 2004 was appointed to the World Health Organisation (WHO) Commission on Intellectual Property Rights, Innovation and Public Health (C.I.P.I.H).
He was for 12 years a member of The UK Government regulatory agency …The Medicines Commission. … also an advisor to the Cabinet Office on the Human Genome project ;a member of the Prime Minister’s Task force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the UK Government Advisory Group on Genetics Research
For 10 years until September 2004 he was Director General of the Association of the British Pharmaceutical Industry (ABPI) a member of Council of IFPMA and the Board of EFPIA.
In 2005 he was the winner of the SCRIP Life Time Achievement award for his contribution to the pharmaceutical sciences and industry.